| Monday | ||||
Catch up on today's… Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mirum Pharmaceuticals (MIRM) initiated with a Buy at H.C. Wainwright. 2. ORIC Pharmaceuticals (ORIC) initiated with a Buy at H.C. Wainwright. 3. Store Capital (STOR) initiated with an Outperform at Evercore ISI. 4. Geron (GERN) initiated with a Buy at Stifel. 5. Purple Innovation (PRPL) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here. | ||||
H.C. Wainwright analyst… H.C. Wainwright analyst Ed Arce initiated coverage of Mirum Pharmaceuticals with a Buy rating and $52 price target. The analyst expects one New Drug Application filing with two indications, Allagille syndrome and progressive familial intrahepatic cholestasis to be accepted in Q1 of 2021, followed by a six month Priority Review leading to U.S. approval and launch in second half of 2021. He sees this as a "substantial potential catalyst" for the shares. | ||||
| Thursday | ||||
Piper Sandler analyst… Piper Sandler analyst Yasmeen Rahimi initiated coverage of Mirum Pharmaceuticals with an Overweight rating and $77 price target. The analyst sees 280% upside given the "key imminent event" of a New Drug Application submission for Mirum's IBAT inhibitor maralixibat in the pediatric cholestasis disease Alagille syndrome and its planned MAA submission for maralixibat in PFIC2 in Europe. Rahimi's "conviction is high" on these further maralixibat indications. | ||||
| Over a month ago | ||||
Virtual Meeting to be… Virtual Meeting to be held on July 2 hosted by Roth Capital. | ||||
Virtual Meeting to be… Virtual Meeting to be held on July 2 hosted by Roth Capital. | ||||
Virtual Meeting to be… Virtual Meeting to be held on June 26 hosted by Roth Capital. | |
Baird analyst Brian… Baird analyst Brian Skorney initiated coverage of Mirum Pharmaceuticals with an Outperform rating and $30 price target. The company's maralixibat looks poised to become first approved treatment for Alagille syndrome following a positive pre-NDA meeting with the FDA in late-2019, Skorney said. He believes it is "very likely" that the company's new drug application is approved in 2021, providing entry into a market opportunity that exceeds $500M, the analyst added. | |
Virtual Meeting to be… Virtual Meeting to be held June 23 hosted by Roth Capital. | |
Virtual Meeting to be… Virtual Meeting to be held on June 26 hosted by Roth Capital. | |
Virtual Meeting to be… Virtual Meeting to be held June 23 hosted by Roth Capital. |